ArticleOncology letters2026
Pathological transformation of rectal adenocarcinoma to choriocarcinoma in a male patient: A case report and review of the literature.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choriocarcinoma associated with poorly differentiated somatic cell carcinoma is a rare disease and there are limitations in its clinical management. The present study describes the case of a 62-year-old male patient with rectal adenocarcinoma; after undergoing three lines of standard colorectal cancer treatment, the rectal adenocarcinoma exhibited abnormal differentiation into choriocarcinoma with a notable increase in serum β-human chorionic gonadotropin (β-hCG). The patient underwent two cycles of EMP/CO chemotherapy (etoposide, methotrexate, cisplatin/cyclophosphamide and vincristine); the standard treatment regimen for choriocarcinoma is EMA/CO (etoposide, methotrexate, actinomycin D/cyclophosphamide and vincristine), whereas in the present case, cisplatin was used in place of actinomycin D. Subsequently, β-hCG levels exhibited a marked decrease. After the first cycle of chemotherapy, the β-hCG level decreased from >15,000 mIU/ml to 4,109 mIU/ml. Notably, the second cycle of chemotherapy was delayed due to fever and perianal abscess, after which the β-hCG level rose again to >15,000 mIU/ml; yet, after chemotherapy on days 1-2 of the second cycle, the β-hCG level decreased again to 11,900 mIU/ml. However, due to poor tolerance and rapid disease progression, the patient was unable to continue receiving treatment and ultimately died. Given the rarity and clinical intractability of this disease, the relevant literature was reviewed to offer insights into its mechanism, diagnosis and treatment. The current case report illustrates the pathological transformation from rectal adenocarcinoma to choriocarcinoma in a male patient, which provides evidence for the abnormal differentiation of somatic cell carcinoma into choriocarcinoma. Concurrently, post-treatment β-hCG level changes validated the therapeutic efficacy of EMP/CO. Furthermore, given the promising advances in antiangiogenic and immunotherapy research, these therapeutic approaches warrant further exploration alongside chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.